Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 49

Sort by

Sort Order Select

Journal Articles

FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study

Blood (2021) 138 (Supplement 1): 633.

https://doi.org/10.1182/blood-2021-148369

Published: 2021

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

Characterization of Leukemic Stem Cells Heterogeneity in Chronic Myeloid Leukemia

Rebecca Warfvinge, MSc, Mikael Sommarin, Parashar Dhapola, MSc, Ulrich Pfisterer, PhD, Linda Geironson Ulfsson, PhD, Fatemeh Safi, MSc, Ram Krishna Thakur, PhD, Johan Richter, MD PhD, Göran Karlsson, PhD

Blood (2019) 134 (Supplement_1): 4140.

https://doi.org/10.1182/blood-2019-130956

Published: 2019

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Markus Pfirrmann, Francois-Xavier Mahon, MD PhD, Joelle Guilhot, PhD, Johan Richter, MD PhD, Francis J. Giles, MD MB, FRCPath, Andreas Hochhaus, MD, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Giuseppe Saglio, MD PhD, Weiping Deng, Darshan Dalal, MPH, MD PhD, Susanne Saussele, MD

Blood (2017) 130 (Supplement 1): 1601.

https://doi.org/10.1182/blood.V130.Suppl_1.1601.1601

Published: 2017

Journal Articles

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N. E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson

Blood (2017) 129 (17): 2384–2394.

https://doi.org/10.1182/blood-2016-07-728873

Published: 2017

Includes: Supplemental data

Journal Articles

IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Helena Ågerstam, Nils Hansen, Sofia von Palffy, Carl Sandén, Kristian Reckzeh, Christine Karlsson, Henrik Lilljebjörn, Niklas Landberg, Maria Askmyr, Carl Högberg, Marianne Rissler, Kimmo Porkka, Hans Wadenvik, Satu Mustjoki, Johan Richter, Marcus Järås, Thoas Fioretos

Blood (2016) 128 (23): 2683–2693.

https://doi.org/10.1182/blood-2015-11-679985

Published: 2016

Includes: Supplemental data

Journal Articles

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Blood (2016) 128 (22): 787.

https://doi.org/10.1182/blood.V128.22.787.787

Published: 2016

Journal Articles

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

Blood (2016) 128 (22): 789.

https://doi.org/10.1182/blood.V128.22.789.789

Published: 2016

Journal Articles

IL1RAP Antibodies Block IL1-Induced Expansion of Primitive CML Cells and Display Therapeutic Effects in Xenograft Models

Helena Ågerstam, Nils Hansen, Sofia Von Palffy, Carl Sandén, Kristian Reckzeh, Christine Karlsson, Henrik Lilljebjörn, Niklas Landberg, Maria Askmyr, Carl Högberg, Marianne Rissler, Kimmo Porkka, Hans Wadenvik, Satu Mustjoki, Johan Richter, MD, Marcus Järås, Thoas Fioretos

Blood (2016) 128 (22): 1118.

https://doi.org/10.1182/blood.V128.22.1118.1118

Published: 2016

Journal Articles

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

Anne-Sophie Bouillon, Monica S. Ferreira, PhD, Shady Adnan Awad, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Thoas Fioretos, Sebastian Hummel, Mirle Schemionek, PhD, Satu Mustjoki, MD PhD, Fabian Beier, MD, Tim H. Brümmendorf, MD

Blood (2016) 128 (22): 4243.

https://doi.org/10.1182/blood.V128.22.4243.4243

Published: 2016

Journal Articles

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Niklas Gunnarsson, MD, Martin Höglund, MD PhD, Leif Stenke, MD PhD, Fredrik Sandin, MSc, Magnus Bjorkholm, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD, Anders Själander, MD PhD

Blood (2016) 128 (22): 1896.

https://doi.org/10.1182/blood.V128.22.1896.1896

Published: 2016

Journal Articles

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Blood (2016) 128 (22): 627.

https://doi.org/10.1182/blood.V128.22.627.627

Published: 2016

Journal Articles

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Anna Kreutzman, PhD, Perttu Koskenvesa, MD, Kasanen Tiina, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, MD PhD, Leif Stenke, MD PhD, Lene Udby, MD, Bjorn T. Gjertsen, MD PhD, Kourosh Lotfi, MD, Berit Markevän, MD PhD, Jeroen Janssen, MD, Tim Brümmendorf, MD, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3069.

https://doi.org/10.1182/blood.V128.22.3069.3069

Published: 2016

Journal Articles

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Niklas Gunnarsson, MD, Martin Hoglund, MD PhD, Leif Stenke, MD PhD, Solveig Wallberg Jonsson, MD PhD, Fredrik Sandin, PhD, Magnus Bjorkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevarn, MD, Ulla Olsson-Stromberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD PhD, Anders Sjalander, MD PhD

Blood (2015) 126 (23): 1586.

https://doi.org/10.1182/blood.V126.23.1586.1586

Published: 2015

Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2015) 126 (23): 343.

https://doi.org/10.1182/blood.V126.23.343.343

Published: 2015

Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD

Blood (2015) 126 (23): 477.

https://doi.org/10.1182/blood.V126.23.477.477

Published: 2015

Journal Articles

Modeling Chronic Myeloid Leukemia in Immunodeficient Mice Reveals an Inflammatory State with Expansion of Aberrant Mast Cells and Accumulation of Pre B Cells

Maria Askmyr, PhD, Helena Agerstam, PhD, Henrik Lilljebjörn, PhD, Nils Hansen, PhD, Christine Karlsson, PhD, Niklas Landberg, Carl Hogberg, PhD, Carin Lassen, Msc, Marianne Rissler, Johan Richter, MD PhD, Mats Ehinger, MD PhD, Marcus Jaras, PhD, Thoas Fioretos, MD PhD

Blood (2014) 124 (21): 3132.

https://doi.org/10.1182/blood.V124.21.3132.3132

Published: 2014

Journal Articles

Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries

Torsten Dahlén, MD, Gustaf Edgren, MD PhD, Martin Höglund, MD PhD, Mats Lambe, MD PhD, Magnus Björkholm, MD PhD, Fredrik Sandin, PhD, Anders Själander, MD PhD, Johan Richter, MD PhD, Lotta Ohm, MD PhD, Magnus Bäck, MD PhD, Leif Stenke, MD PhD

Blood (2014) 124 (21): 3134.

https://doi.org/10.1182/blood.V124.21.3134.3134

Published: 2014

Journal Articles

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Blood (2014) 124 (21): 812.

https://doi.org/10.1182/blood.V124.21.812.812

Published: 2014

NARROW

FINAL Analysis of a PAN European STOP Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI Study

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Characterization of Leukemic Stem Cells Heterogeneity in Chronic Myeloid Leukemia

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Molecular Recurrence-Free Survival (MRecFS) Following Imatinib Vs. Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Matched Analysis of Patients in EURO-SKI and Enestfreedom

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

IL1RAP antibodies block IL-1–induced expansion of candidate CML stem cells and mediate cell killing in xenograft models

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

No Differences in Molecular Relapse-Free Survival after Stopping Imatinib Treatment of Chronic Myeloid Leukemia Between Patients with Prior 4.5 Log Reduction (MR4.5) but Detectable and Patients with Undetectable Disease in the EURO-SKI Trial

IL1RAP Antibodies Block IL1-Induced Expansion of Primitive CML Cells and Display Therapeutic Effects in Xenograft Models

Telomere Length Shortening in the CML Leukemic Stem Cell Compartment Correlates with the Respective Clone Size: Evidence for Early Vs. Late Chronic Phase

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Modeling Chronic Myeloid Leukemia in Immunodeficient Mice Reveals an Inflammatory State with Expansion of Aberrant Mast Cells and Accumulation of Pre B Cells

Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only